Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Recruiting

Phase 3

CadisegliatinCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

Sponsor:

vTv Therapeutics

Code:

NCT06334133

Conditions

Diabetes Mellitus, Type 1

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cadisegliatin 800 mg QD

Cadisegliatin 800 mg BID

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by vTv Therapeutics on 2025-07-18.